Pathway Genomics Acquires FDA-Cleared Illumina MiSeqDx Next-Generation Sequencing Systems
SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced it has added the Illumina MiSeqDx to its fleet of next-generation sequencing systems.
“Our investment in the first FDA-cleared sequencer is part of our strategic plans to grow our next-generation sequencing capacity on multiple platforms for genetic testing”
Designed and validated for the clinical market, the benchtop sequencing system will optimize the company’s ability to develop and run diagnostic applications. It enables sample multiplexing, maximizing operator efficiency and increasing throughput.
“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.
Allowing for a highly efficient workflow with minimal hands-on time, the MiSeqDx prepares DNA for sequencing following a streamlined process that includes ready-to-use reagents.
“Our investment in the first FDA-cleared sequencer is part of our strategic plans to grow our next-generation sequencing capacity on multiple platforms for genetic testing,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “We have a full suite of services ready to be launched on the MiSeqDx, which will include both single genes and comprehensive panels.”
About Pathway Genomics Corporation
As a CLIA and CAP accredited clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing industry. Pathway Genomics’ testing services cover a variety of conditions including cardiac health, cancer risk, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.